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Foot-and-mouth disease (FMD) is a highly contagious disease of cloven-hoofed animals
that causes severe economic losses in the livestock industry. Currently available vaccines
are based on the inactivated FMD virus (FMDV). Although inactivated vaccines have been
effective in controlling the disease, they have some disadvantages. Because of these
disadvantages, investigations are being made to produce vaccines in low containment
facilities. The use of recombinant empty capsids (also referred as Virus Like Particles,
VLPs) has been reported to be a promising candidate as a subunit vaccine because
it avoids the use of virus in the vaccine production and conserves the conformational
epitopes of the virus. Mignaqui and collaborators have produced recombinant FMDV
empty capsids from serotype A/ARG/2001 using a scalable technology in mammalian
cells that elicited a protective immunity against viral challenge in a mouse model.
However, further evaluation of the immune response elicited by these VLPs in cattle
is required. In the present work we compare the effect that VLPs or inactivated
FMDV has on bovine dendritic cells and the humoral response elicited in cattle after
a single vaccination.
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INTRODUCTION
Foot-and-mouth disease (FMD) is an infectious-contagious, acute, and febrile disease of cloven-
hoofed animals such as cattle, pigs, sheep, and deer, whose etiologic agent is Foot-and-Mouth
Disease Virus (1, 2). The disease is endemic in many parts of the developing countries and is
absent in countries from North and Central America, Australia, and Europe. FMD results in,
loss of productivity and severe restrictions to international trade and pose a serious and constant
threat to livestock industries, since FMD spreads rapidly giving rise to large scale outbreaks (3).
Quattrocchi et al. FMDV VLPs on ALDCs
Vaccination with the inactivated virus is still the main strategy
for disease control in countries where the disease is endemic
(4, 5). Although inactivated vaccine has been effective in
controlling the disease, it has some disadvantages. Among
them, the need for expensive biosecurity facilities for
vaccine production which requires constant investments in
manufacturing plant up-grades and personnel qualifications
together with the risk of viral escape from the production
facilities or live virus contamination of the vaccines. Also, the
storage and supply of the inactivated vaccine are cold-chain
dependent because of the low vaccine stability at ambient
temperatures and the production requires high purification
process to remove the non-structural proteins from vaccine
formulations to be able to discriminate vaccinated from
infected cattle (6, 7). Moreover, many countries have regulatory
restrictions that prohibit the production of inactivated FMD
vaccines in their mainland. Because of these disadvantages,
investigations are being made to produce vaccines as
immunogenic as the inactivated viral vaccine in low containment
facilities. FMDV recombinant empty capsids (VLPs) seem
a promising alternative since they contain all the protein
immunogenic sites of the virus, but lack the infectious nucleic
acid and natural FMDV empty capsids have been shown to be
as immunogenic as virions. Mignaqui et al. (8) have produced
recombinant FMDV serotype A/ARG/2001 VLPs with high
yield, using Transient Gene Expression (TGE) in mammalian
cells. These empty capsids triggered a protective immune
response against viral challenge comparable to the response
elicited by the same amount of inactivated virus in a mouse
model. A key step to move forward through the development of
a novel vaccine against FMD based on VLPs is to demonstrate
that the immune response elicited by these novel recombinant
antigens is similar to the response to inactivated virus in
the natural host.
In this regard, dendritic cells (DCs) are key players in
initiating immune responses after infection or vaccination
since they have unique abilities to stimulate naïve T
cells and thus represents an important immune response
player to study together with the immune response in the
host animal.
In the present work, we compare the effect of FMDV
recombinant empty capsids produced by Mignaqui and
collaborators, with the response from inactivated virus on
bovine DCs and the humoral response they induce in bovines,
in order to gain insight about the immunogenicity of these novel
recombinant particles in the natural host.
MATERIALS AND METHODS
Experimental Design
Afferent lymph dendritic cells (ALDCs) and peripheral blood
mononuclear cells (PBMCs) were obtained from the same
prime vaccinated calf as described below. These cells were used
to test in vitro VLPs immunogenicity by assessing dendritic
cell activation and T cells proliferation and to compare it
with the response induced by inactivated FMDV contained in
the commercial vaccine. Other groups of naïve calves were
vaccinated using VLPs or inactivated antigen, both formulated
with commercial adjuvant, in order to compare the antibody
response of both formulations.
Harvesting ALDCs
Holando-Argentino calves were used to obtain afferent lymph
dendritic cells (ALDCs) as described before (9). Briefly: 2 months
before cannulation surgery, prescapular lymph nodes were
removed. After that time, cannulation surgery was performed
on the vessel resulting from anastomosis between afferent
and efferent vessels, by inserting a cannula. Lymph was
collected in a flask containing heparin and antibiotics. The
flasks were replaced daily and lymph cells were concentrated
by centrifugation on histopaque-1083 (Sigma) gradient. Cells
were cryopreserved with fetal calf serum 10% DMSO under
liquid nitrogen until use. Approximately 10–15% of the
lymph cells were ALDCs characterized by flow cytometry
as DEC205+/FSChigh/CD11c+/CD8– as reported previously
(9, 10). Calves were vaccinated once with the commercial vaccine
regularly used in the national vaccination campaign against
FMD, a few months prior to cannulation.
Peripheral Blood Mononuclear Cells
(PBMCs) Isolation
Heparinized blood was obtained by jugular vein puncture (from
cannulated animal). Blood was centrifuged on Lymphoprep
(Ficoll-Paque Plus 1.077 g/ml GEHealthcare) gradient. The white
band containing PBMCs was washed and cryopreserved with
fetal calf serum 10% DMSO under liquid nitrogen until use.
Recombinant Empty Capsids Production
VLPs were obtained as described previously (8). Briefly,
suspension-growing 293-6E cells were transiently transfected
with pTT5-P12A3C plasmid, cells were harvested 48 h post
transfection. After centrifugation, cell pellets were lysed by freeze
and thawed cycles and analyzed for protein expression. These
lysates were used as source of empty capsids and lysates from
non-transfected cells were used as mock control.
Inactivated Virus Production
FMDV serotype A/ARG/2001 was grown in BHK-21 cell
cultures in Biogénesis-Bagó high biosecurity facilities. Then
inactivation was carried out by Binary Ethylenimine (BEI)
treatment and inactivated FMDV (iFMDV) was purified
by ultrafiltration/diafiltration.
Regulation of Co-stimulatory Molecules on
ALDCs
lymph cells were incubated for 16 h with iFMDV serotype
A/ARG/2001, VLPs, mock or Poly I:C as positive control,
in comparable amounts (1µg/ml) in IMDM (Gibco) cell
culture medium with 10% fetal calf serum (FCS). Regulation
of co-stimulatory molecules CD40, CD86, and MHCII, was
measured after overnight incubation of lymph cells with
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FIGURE 1 | Surface expression of CD40, CD86, and MHCII co-stimulatory molecules on afferent lymph dendritic cells (ALDCs) (FSChigh/DEC205+/CD11c+) after
overnight incubation with iFMDV or empty capsids, is shown. (A) Gating strategy used for cytometric analysis. Co-stimulatory regulation molecules were analyzed in
R2 region (B) Regulation of CD40 molecule (C) Regulation of CD86 molecule. (D) Regulation of MHCII molecule. Results in (B–D) are expressed as the mean
fluorescence intensity plus Standard Deviation (SD) of four replicates in two independent assays. Mock group were lymph cells incubated with supernatant from
non-transfected cells. Poly (I:C) was used as a positive control. *Significant difference p < 0.05, **significant difference p < 0.01. (E) One representative histogram of
each group is shown.
antigens using an indirect surface staining performed with
mouse monoclonal antibodies anti CD40, CD86, and MHCII
(SEROTEC), and then anti mouse IgG-Pe conjugated (BD).
Finally anti-DEC205 APC-conjugated and anti CD11c FITC-
conjugated monoclonal antibodies were added. Cells were
fixed with 0.2% paraformaldehyde and were acquired using
FACScalibur cytometer and CellQuest software (BD). The
analysis of co-stimulatory molecules expression was detected
specifically in the FSChigh/ DEC205+/CD11c+ cell population.
Gating strategy is shown in Figure 1A.
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FIGURE 2 | Co-cultures of lymph cells incubated with iFMDV or empty capsids, and CFSE-labeled PBMCs. (A) Results are expressed as percentage of proliferating
PBMCs. Mock = ALDCs incubated with supernatant from non-transfected cells. ** and *** represent a significant difference (p < 0.01 and p < 0.001 respectively)
regarding mock control. Mean of triplicates + SD of one representative graph of two independents assays, are shown. (B) A representative dot plot of CFSE lost for
each group is shown.
Proliferation Assessment
iFMDV or VLPs stimulated ALDCs (same procedure as used
for regulation of co-stimulatory molecules), were washed
with PBS and then with fresh RPMI 1640 (Gibco) 10%
FCS medium, and put in contact with Carboxyfluorescein
succinimidyl ester (CFSE)-charged PBMCs from the same
animal. PBMCs proliferative response was evaluated according
to the progressive CFSE staining reduction by flow cytometry,
after 5 days incubation at 37◦C in a CO2 incubator. Incubation
of PBMCs with Concanavalin A (ConA) was used as
positive control.
Humoral Response Assessment
Seronegative calves 8–10 months old, were vaccinated by
subcutaneous route with a final volume of 2ml/dose of
formulations containing 25µg/dose of iFMDV or VLPs
(n = 4, per group) with a water-in-oil single emulsion adjuvant
included in the commercial vaccine currently used in eradication
campaigns in Argentine (Biogenesis-Bagó). Calves were
bleed at 15, 25, 35, and 45 days post vaccination (dpv) and
humoral response were measured by liquid phase ELISA (11).
Briefly: Greiner Microlon R© plates were coated overnight at
4◦C with 1/4,000 dilution of rabbit anti-FMDV serum in
carbonate-bicarbonate buffer, pH 9.6. After washing with
0.05% Tween-20/phosphate buffered saline (PBST), plates were
blocked with PBST/1% ovalbumin (blocking buffer) for 30min
at 37◦C. Sera were serially diluted (first dilution 1:10 and then
1:5 dilutions) in blocking buffer and a fixed amount of iFMDV
was added. After 1 h incubation at 37◦C with shaking, the
virus-antibody mixtures were transferred to the blocked plates,
and incubated for 1 h at 37◦C. A 1/1,000 dilution of guinea
pig anti-FMDV serum in PBS/2% normal bovine serum/2%
normal rabbit serum was added for detection, followed by
1 h incubation at 37◦C. Plates were washed and peroxidase-
conjugated anti-guinea pig IgG (Jackson ImmunoResearch R©)
serum 1/2,000 diluted in the same buffer was added, followed
by 1 h incubation at 37◦C. OPD/H2O2 was used as peroxidase
substrate and A492 was measured in a microplate reader.
Positive and negative bovine reference sera were included in
each test, for validation. Antibody titers were expressed as the
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negative log10 of the highest dilution of serum that causes
more than 50% inhibition of color development than in the
control samples.
Statistics
ANOVA and Bonferroni post ANOVA tests were used to
compare data among groups. P < 0.05 was considered as an
indicator of significant difference.
Ethics Statement
Experiments involving animals were performed in accordance
with protocols approved by the INTA’s Ethical Committee of
Animal Welfare (CICUAE Permit numbers: 06/2013).
RESULTS
FMDV Empty Capsids Up-Regulates
Co-stimulatory Molecules
Lymph cells were incubated with the same concentration
of iFMDV or empty capsids. After staining of cells with
fluorochrome-conjugated antibodies, anti DEC205, anti CD11c,
and MHCII, CD40 or CD86, the analysis of co-stimulatory
molecules was made on FSChigh/ DEC205+/CD11c+ cells. As
shown in Figure 1, iFMDV and empty capsids significantly up-
regulates co-stimulatory molecules CD40, CD86, andMHCII. As
expected, Poly I: C significantly upregulated the expression of the
three molecules.
ALDCs Incubated With FMDV Empty
Capsids Are Capable of Stimulating
PBMCs Proliferation
ALDCs were incubated with the same concentration of iFMDV
or empty capsids, then cells were washed repeatedly in order
to eliminate any free inactivated virus or capsids not associated
with the ALDCs. The ALDCs were then put in culture with
CFSE-labeled PBMCs from the same animal. After 5 days
incubation, an anamnestic response was detected. The percentage
of proliferating T cells from a vaccinated calf was significantly
increased, according to the measurement of CFSE stain loss
(Figure 2). Concanavalin A was added directly on PBMCs as a
positive proliferation control.
FMDV Empty Capsids and IFMDV Are
Capable of Stimulating a Similar Humoral
Response in Bovines
A dose of 25 µg of iFMDV or empty capsids was used
according to previous reports indicating that commercial
tetravalent vaccines inducing good levels of protection contain
approximately this amount of inactive virus (12). When empty
capsids or iFMDV were formulated with commercial adjuvant
and inoculated in FMDV seronegative bovines, a specific
humoral response was induced in both groups. Antibody
titres (log10) ranged between 2.60 and 2.84 for empty capsids
vaccinated group, and 2.60–2.9 for iFMDV group. In both
FIGURE 3 | Antibodies titers against FMDV evaluated at 0, 15, 25, 35, and 45
dpv by Liquid phase ELISA in vaccinated cattle. Bovines were inoculated with
inactivated FMDV () or empty capsids () formulated with commercial
adjuvant. Results are expressed as mean plus SD error bars of 4 animals.
groups, these titres of antibodies were maintained up to 45 dpv,
without booster immunization (Figure 3).
According with the National Service of Health and
Agricultural Quality (SENASA), these antibody titers correspond
to a percentage of expected protection between 91.6 and
96.6% (13).
DISCUSSION
In the last years, considerable efforts have been made to develop
an effective and safe vaccine against FMD, especially concerning
the need to avoid the use of large quantities of live virus because
of the risk and the cost of production. Since natural FMDV
empty capsids have been shown to be as immunogenic as virions,
several approaches have reported the use of empty capsids as
an alternative vaccine. In 2013, Mignaqui and collaborators,
produced FMDV recombinant empty capsids from serotype
A/ARG/2001 in a mammalian expression system, and evaluated
them in the mouse model that has been widely used and it has
been proved to be a useful tool to predict the immune response
against FMDV in bovines (14–17). Humoral responses elicited by
FMDV empty capsids in mice were high and empty capsids were
fully protective against viral challenge (8). Nevertheless, immune
response elicited to these empty capsids has not been assessed
in bovines.
This study was undertaken to evaluate the ability of FMDV
recombinant empty capsids serotype A/ARG/2001, to stimulate
bovine dendritic cells and consequently generate a protective
humoral immune response, in order to determine if these VLPs
would be a good antigen candidate for vaccine development.
DCs play a main role in the adaptive immune response
development, since they are highly specialized in taking,
processing and presenting antigens to naive T lymphocytes
(18). In vitro differentiated DCs from monocytes (MoDCs) are
a broadly accepted model, nevertheless, it has been reported
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that they functionality could be affected by the treatments
used in order to differentiate them (9, 19–21). Moreover,
MoDC are different cells from conventional DC (cDCs) (22)
that differentiate in peripheral tissues only in inflammatory
conditions, and they do not migrate in the lymph or do it
weakly (23) while ALDC are mainly cDC. Charleston and
collaborators (9) have developed a technique to cannulate
bovine afferent lymphatic vessels, allowing collecting of large
volumes of lymph containing afferent lymph dendritic cells
(ALDCs). This work was carried out using ALDCs which are
reported to be a more physiological alternative to in vitro
differentiated dendritic cells, since they are not subjected to
long periods of culture, enzymatic treatment or separation
treatments (9, 10).
It has been reported that VLPs contain the complete repertoire
of FMDV epitopes with the particulate and repetitive structure
of the virus (4, 24). We investigated whether VLPs and
inactivated virus would induce similar immune responses. These
are important studies to understand if the inactivated RNA
genome still present in the inactivated virus provided additional
immune stimulation compared to empty capsids. In this sense,
we demonstrate that empty capsids are capable of up-regulating
co-stimulatory molecules CD40, CD86, and MHCII on the
ALDCs surface in the same way as inactive virus. It is known
that CD40 signaling induces changes in DCs that make them
more effective antigen presenting cells, such as up-regulation of
MHC class II and co-stimulatory molecules CD80 and CD86 (25,
26). Accordingly, incubation of ALDCs charged with VLPs or
inactive virus, produced a proliferative response when they were
incubated with CFSE- labeled PBMCs from the same animal.
Taking into account that the donor calf for ALDCs and PBMCs,
received one vaccination with the FMD commercial inactivated
vaccine previous to the cannulation surgery and the PBMCs
period of in vitro culture, we hypothesize that the observed
proliferation correspond to memory T cells being stimulated
by ALDCs. These results indicate that FMDV VLPs are
processed and presented to T lymphocytes in a very similar way
to iFMDV.
As expected, VLPs were able to produce a high humoral
response like the iFMDV when antigens were formulated with
a commercial oil adjuvant and antibody response was assessed in
vivo in FMDV seronegative cattle. Indeed, the humoral response
elicited by VLPs lasted the same time post vaccination as the one
elicited by iFMDV, in the period analyzed.
Even though the animals were not challenged, the antibody
titers achieved by VLPs and iFMDV are above the passmark of
approval in potency test of FMD vaccines in Argentina according
to statistical correlation previously reported (27).
Our results are in agreement with data from other groups,
who reported that recombinant empty capsids of FMDV from
different serotypes, produced in different systems, were capable
of inducing humoral responses and even fully or partially
protecting natural hosts against challenge (3, 28, 29).
Considering the immunogenicity of these VLPs in cattle
and the fact that their production is scalable and simple, these
empty capsids are a promising antigen to replace the current
inactivated vaccine.
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